Print

Vivo Ventures Leads $30 Million Funding of Shanghai Jingfeng Pharma  
11/6/2012 6:24:40 AM

by Richard Daverman, PhD

November 5, 2012 -- Vivo Ventures, the California-China healthcare venture capital company, is the lead investor in a 190 million RMB ($30 million) funding round for Shanghai Jingfeng Pharmaceutical Co., according to Venture Wire. In January, Vivo closed Vivo Ventures VII, a $375 million fund. It pledged to allocate 45% of that to China life science companies. Founded in 2003, Shanghai Jingfeng Pharma is GMP-certified by the SFDA to make sodium hyaluronate API. More details....


//-->